Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of July 2019, specifically dated July 23, 2019. The report details the execution of a Sales Agreement with SVB Leerink LLC to facilitate an "at the market" offering program for the Company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the potential capital raise:
- Maximum Aggregate Gross Proceeds: Up to $60.0 million.
- Commission to Sales Agent: Up to 3.0% of gross proceeds.
- Security Type: American Depositary Shares (ADSs), each representing 10 ordinary shares.
Material Changes
The material change reported is the establishment of a new equity financing mechanism. On July 23, 2019, the Company entered into a Sales Agreement allowing for the sale of ADSs through SVB Leerink. This agreement is issued pursuant to the Company's shelf registration statement on Form F-3 (File No. 333-226278), as supplemented by a prospectus supplement dated July 23, 2019.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates the Company's intent to raise capital through an "at the market" program, providing flexibility to sell shares from time to time. Both the Company and SVB Leerink retain the right to suspend or terminate the offering at any time upon proper notice.
Risks and Contingencies: The Sales Agreement includes customary representations, warranties, and covenants. The Company has agreed to indemnify SVB Leerink against certain liabilities under the Securities Act of 1933 and the Securities Exchange Act of 1934. The filing explicitly states it is not an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current status of the $60.0 million "at the market" offering program and the amount of ADSs sold to date.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses and conditions.
- Confirm the Company's current cash position and liquidity needs to understand the urgency of this capital raise.
- Check subsequent filings for any actual sales executed under this agreement and the resulting dilution to existing shareholders.